mr-b, you seem pretty technical;
yes, today was very good technically;
especially after yesterday; maybe the picture
clears a bit, maybe the interval, 2/28 - 3/11; was
the consolidation interval associated with the earnings
move interval 2/06 - 2/27; if so, and with low volume,
these market markers are playing it smart, and cagey.
Horray, volume still light, ... very light ..,
probably a good thing, meaning the market markers have
the stock under their control;
I'm always nervous.
SAGES stands for Society of American Gastrointestinal and Endoscopic Surgeons. Given where Pinpoint is most applicable you can see how important this meeting is to Novadaq. I am checking to see when SAGES indicates the 2014 meeting agenda. As with other things, I am hopeful that Pinpoint is on the agenda.
...." I am now hopeful that the Pillar results will be published April 1st just prior to the SAGES annual convention that starts April 2nd."
Endo, what are you referencing?
low of the day now;
20.39; hard to believe that the high of the day
crossed through 21, and looking stronger to move forward;
Someone knows what they are doing here;
as far as market maker algorithms;
Their programs run the stock to 21, taking in some higher orders,
then the algorithms run the price lower, looking for sellers who want out
from the morning pop;
Tough to tell how much price movement is just the same market marker
If this stock flies for any reason, it won't be able to be caught;
closing above 21, should be an indicator of breakout momentum;
no one is selling;
you make a lot of sense;
yesterday's open was down a slight heavy,
and the stock traded quietly higher all day, With today's selling in the averages,
the stock is firmly healthy;
Thursday's investor conference might be an event;
but no doubt, the stock has support;
Bear in mind this is a Canadian company not very well known to the retail investment community in the U.S. You need look not further then the scant daily activity on this message board to see evidence of that fact. However, the stock is not unknown to the institutional investment community which has increased the position it has in the company from 30% two years ago to 72% today. Is the stock being manipulated? Who knows, who cares. All I know is that the pps has increased from $5 two years ago to about $21 today.
On another issue, I am now hopeful that the Pillar results will be published April 1st just prior to the SAGES annual convention that starts April 2nd.
nvdq appears to possess break out technology, the stock price is reasonable,
the management seems prudent and insightful;
my concern is: can such an opportunity really exist in a wall street environment
that is loaded with crooks ?
Judging by the investor day conference and other webcast presentations, my feeling is that a successful Pillar lll trial will clinch Novadaq's preeminence in the operating room across a wide array of procedures, not just colorectal.
Sentiment: Strong Buy
At last week's RBC Capital Markets Healthcare Conference Arun mentioned to Doug Miehm that there will be a "phase III-type trial" beginning soon and they will discuss that in the Q1 CC. This must be the next stage of PILLAR he's referring to.